PubMed Health⌕ Search

PubMed · 17032128

Westgard multirule for calculated laboratory tests.

Abstract

BACKGROUND: In clinical laboratories, many test results such as low-density lipoprotein (LDL)-cholesterol can be calculated using the results of specifically measured tests. However, quality control programs deal only with measured tests and there is no adequate quality assessment procedure for calculated tests. I aimed to apply the Westgard multirule to calculated tests as a part of routine quality procedures. METHODS: I prepared a Levey-Jennings chart for calculated tests and all their measured components (Equation chart) and then applied the Westgard multirule to these tests. RESULTS: Applying the Westgard multirule to calculated LDL-cholesterol (and other calculated tests) was simple, and increased the reliability of the results of the calculated tests. CONCLUSIONS: Checking the reliability of only measured tests by quality control procedures before reporting patient results may be inadequate. Applying the Westgard multirule to calculated tests as part of total quality management will increase the reliability of test results.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Abdurrahman Coskun. 2006. Westgard multirule for calculated laboratory tests.. https://doi.org/10.1515/cclm.2006.233

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Molecular biology of PCSK9: its role in LDL metabolism.

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

Cholesterol, LDL↗

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.

Statins are normally administered for the treatment of dyslipidemia on a daily basis. This standard dosing regimen is well tolerated by most patients. Occasionally, patients discontinue therapy secondary to side effects, most commonly myalgias. We describe 2 patients who were unable to tolerate daily atorvastatin therapy secondary to myalgias and were subsequently treated with rosuvastatin administered on Mondays, Wednesdays, and Fridays, with resolution of adverse effects. Significant reductions in serum low-density lipoprotein cholesterol levels were observed in the 2 patients despite the alternate-day dosing regimen. Rosuvastatin was chosen because of its long half-life (19 hours) and very high potency.

Cholesterol, LDL↗